We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Panel Shoots Down Second HIFU Prostate Cancer Treatment
FDA Panel Shoots Down Second HIFU Prostate Cancer Treatment
SonaCare Medical’s hopes of marketing a new treatment for prostate cancer were dealt a setback Wednesday when an FDA advisory group recommended against approving the company’s Sonablate 450.